Indium In-111 oxyquinoline is a radiopharmaceutical diagnostic agent used for radiolabeling autologous leukocytes as an adjunct in the detection of inflammatory processes to which leukocytes migrate. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline.
- Mechanism
- Curator reviewed
Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.
- Primary indication
- Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.Curator reviewed · 1 structured indication
- Formula / weight
- C27H18InN3O3 · 543.364 g/mol (avg)
- First approval
- United States, 1985
- Also known as
- In-111 oxyquinoline · Indium (In111) oxine · Indium 111In oxyquinoline · Indium in 111 oxyquinoline · Indium In-111 oxine
- Brand names
Resolves to
AEGSYIKLTCZUEZ-FZTWWWDYSA-KSMILES[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2What you can answer from here — as of August 31, 2026
Which other approved drugs treat the same conditions as Indium In-111 oxyquinoline, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account